Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron CFO 'pleased' with reformulation of degenerative diseases treatment

Michael Hunt, chief financial officer for the stem cell specialist ReNeuron Group Plc (LON:RENE) updates Proactive on two of their clinical programmes.

Hunt says they're preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke.

He also mentions that a new formulation of their human retinal progenitor cell which is being trialled to treat degenerative diseases of the retina, represents a major step forward for them.

 
Meet Rainbow Rare Earths Limited, Eurasia Mining plc, Mariana Resources Ltd., Anglo Asian Mining Plc and Hannan Metals Ltd at our event, London, 09 May 2017. Register here »
View full RENE profile

ReNeuron Group Plc Timeline

Newswire
February 15 2017
Video
October 28 2016
Article
October 28 2016

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use